Studies on the mechanism of trimethoprim-induced hyperkalemia. We examined the effects of trimethoprim (TMP) on metabolic parameters and renal ATPases in rats after a 90 minute infusion (9.6 mg/hr/kg body wt, i.v.) and after 14 days (20 mg/kg body wt/day, i.p.). After one dose of TMP, plasma electrolytes, arterial pH and aldosterone levels were normal, but a natriuresis, bicarbonaturia, and decreased urinary potassium excretion occurred. Na-K-ATPase activity in microdissected segments from these animals was decreased by 36 0.9% in proximal convoluted tubule (PCT) (P < 0.005); decreases of 50 2.1% and 40 1.1% were seen in cortical and medullary collecting tubules (CCT and MCT), respectively (P < 0.005). Na-K-ATPase activity was unaffected in medullary thick ascending limb (MTAL). H-ATPase (in PCT and collecting duct) and H-K-ATPase (in CCT and MCT) activities were not changed. Following chronic TMP administration, plasma potassium increased as compared to control (5.16 0.05 mEq/liter vs. 3.97 0.05 mEq/liter, P < 0.05), however, acid-base status and plasma aldosterone levels were normal. Na-K-ATPase activity was decreased by 45 2.6% in PCT (P < 0.005), 73 2.0% in CCT (P < 0.001), and 53 2.5% in MCT (P < 0.005). Na-K-ATPase activity in MTAL and H-K-ATPase activity in CCT and MCT were unchanged. H-ATPase activity in PCT and MTAL was normal, but in the collecting tubule (CCT and MCT) it was decreased by approximately 25% (P < 0.05). TMP inhibited Na-K-ATPase activity in a dose-dependent fashion in PCT, CCT, and MCT when tubules from normal animals were incubated in vitro with the drug; TMP in vitro did not affect H-ATPase or H-K-ATPase activity. These results suggest that TMP-induced hyperkalemia may result from decreased urinary potassium excretion caused by inhibition of distal Na-K-ATPase in the face of intact H-K-ATPase activity.
Trimethoprim (TMP), one of the two active components of Bactrim®, is a pyrimidine derivative (pKa 7.3) [10] which, when infused into rats, causes a natriuresis and a fall in urinary potassium excretion [11] , In perfused rat-distal tubule, Velázquez et al [11] showed TMP decreased net potassium secretion and transepithelial voltage. In the frog skin, a model of the mammalian collecting duct, TMP decreases short circuit current and Na22 flux. Amiloride was found to competitively displace TMP with a Kd of 46 X io M (Kd of TMP is 53 X iO M) [12] . Recent studies show that TMP also blocks an amiloride-sensitive sodium channel in A6 cell monolayers, a model of mammalian cortical collecting tubule principal cells [13] .
The collecting tubule is the final site for regulation of urinary potassium excretion and urinary acidification [14, 15] . Potassium secretion at this site is modulated by Na-K-ATPase activity and reabsorption is mediated by H-K-ATPase activity [15, 16] . Inhibition of the former results in hyperkalemia and inhibition of the latter would result in kaliuresis. Proton transport in the collecting tubule is controlled by both the H-ATPase and the H-K-ATPase, enzymes found in the a-intercalated cells [15, 16] . As the effect of TMP on these renal transport enzymes is unknown, we examined acute and chronic administration of the drug to rats in microdissected permeabilized nephron fragments. We also studied the direct effect of the drug in vitro.
Methods
Male Sprague-Dawley rats weighing 100 to 200 g were used in this study. All animals had free access to the usual laboratory diet and were given tap water to drink ad libitum, unless otherwise noted.
In vivo studies A. Acute study (single dose intravenous infusion). Animal preparation. Animals were first anesthetized with sodium pentobarbital and ketamine. The femoral vein was then catheterized with PE-50 tubing for continuous infusion; the femoral artery was cannulated for blood samples [17] . A solution containing NaCl (140 mEq/ liter) and KC1 (4 mEq/liter) (pH 7.4) was infused at 15 ml!hr/kg body wt and was the vehicle for TMP. The bladder was cannulated for urine collection to determine glomerular filtration rate (as measured using creatinine clearance) and electrolyte excretion [18] . A blood sample (0.5 ml) was obtained at the midpoint of each urine collection. One hour was allowed for equilibration before the beginning of the clearance collections. Three urine collections (30 mm) were made as baseline data and three collections (30 mm) were obtained during the experimental period. All blood and urinary losses were replaced with the solution described above. The animals were divided into the following groups (N = 6 in each group):
Group 1: Control (cj). The animals received the salt solution intravenously during the baseline and experimental periods.
Group 2: Trimethoprim (TMP). After the baseline period, animals received 0.64 g/liter TMP at a rate of 9.6 mg/hr/kg body wt throughout the experimental period. Previous work has shown that this dose results in a natriuresis and decreased urinary potassium excretion [11] .
B. Chronic study (14 days intraperitoneal administration). Animal preparation. A twenty-four hour urine collection was performed on each animal as baseline after three days on a diet of standard composition (ICN Pharmaceuticals Inc., Costa Mesa, CA, USA) and 0.3% NaCI p.o. ad libitum to prevent volume contraction as we have described [18] . The animals were then divided into the following groups (N = 6 in each group):
Group 1: Control (. The animals were treated daily (x 14 days) with the vehicle described below (0.75 ml, i.p.). Group 2: Trimethoprim (TMP). The animals were treated daily with TMP (20 mg/kg/day, i.p.) for 14 days. TMP (16 mg/mI) was dissolved in 40% propylene glycol, and at the time of injection was diluted to 0.75 ml (total volume) with distilled H20 for i.p.
On the morning of the thirteenth day, the animals were again placed in metabolic cages for a 24-hour urine collection. On the day of the experiment, after receiving the final TMP dose, the animals were anesthetized and blood samples were obtained from the aorta for measurement of pH, pCO2, creatinine, electrolytes, and aldosterone, Arterial blood gas, urine and plasma electrolytes and creatinine were measured as we have published in the past [17, 18] .
Potassium concentration in muscle, renal cortex, and renal medulla was measured by atomic absorption spectrophotometty; plasma aldosterone concentration was determined by radioimmunoassay (COAT-A-COUNT® DPC, Los Angeles, CA, USA) [18] .
Tubules microdissection and enzymatic measurements
Tubules were microdisseeted as we have previously described in detail [18, 19] . In brief, the left renal artery was cannulated and the kidney was perfused for 15 minutes in situ at a rate of 0.7 mI/mm with a balanced salt solution containing 400 U/ml collagenase; 4°C, pH 7.4. The kidney was then cut into 5 X 5x10 mm pyramids along the cortico-papillary axis and incubated in 3 ml of collagenase-albumin containing Hank's solution at 35°C for 12 minutes, pH 7.4. The tissues were continuously bubbled with compressed air (3 psi). After incubation, the pyramids were rinsed and immediately microdissected. Tubule segments were identified as proximal convoluted tubule (PCT), medullary thick ascending limb of Henle's loop (MTAL), cortical collecting tubule (CCT), and medullary collecting tubule (MCT) [18, 19] .
To remove most of the extracellular potassium, nephron segments were incubated for 15 minutes at 37°C (pH 7.4) in potassium-free buffer. The nephron segments were then subjected to a two-step hypotonic-hypothermic shock and ATPase activities were determined after incubation of the segments with y32P-labeled ATP (37°C, 15 mm, pH 7.4). H-ATPase (N-ethylmaleimide-inhibitable), H-K-ATPase (K-stimulated), and Na-K-ATPase (ouabain-inhibitable) were measured by the radiochemical method of Doucet and Marsy [20] as subsequently described by us [21] . All assays were performed at V,1, conditions (12 mM ATP, pH 7.4 and 37°C) [21] .
in vitro study To further examine the direct effect of TMP on the three renal ATPases, additional in vitro studies were performed in a manner we have described for amiloride [19, 22] . Segments of PCT, CCT, and MCT were first microdissected from acclimated normal Sprague-Dawley rats. After the hypotonic-hypothermie shock, tubule segments were pre-incubated for 90 minutes in vitro in 1.2 d of buffer with varying concentrations of TMP (0.01 to 10 mM).
After the preincubation period, the solution was then replaced with one appropriate for the enzyme analysis to be performed (that is, H-ATPase, H-K-ATPase and Na-K-ATPase). ATP (12 mM) plus y32P-ATP was added and the reaction was allowed to proceed for 15 minutes at 37°C, pH 7.4.
Enzyme activity is expressed as pmol/mm tubule length/hour of ATP hydrolyzed. All samples were run in triplicate or quadruplicate and appropriate corrections were made for the blank and for the spontaneous hydrolysis of ATP [21] .
Materials
All chemicals and reagents were obtained from the Sigma Chemical Co. (St. Louis, MO, USA) and were of highest purity. Radiolaheled ATP (high specific activity) was obtained from New England Nuclear (Boston, MA, USA). Trimethoprim was graciously provided by the Roche Laboratories (Nutley, NJ, USA).
Statistics
Statistical significance was assessed using the Student's t-test (paired or unpaired) or analysis of eovariance, where appropriate, with P values of 0.05 or less being significant.
Results
Effects of trimethoprim infusion on metabolic parameters and renal function Acute infusion. There was no significant difference in any of the blood values or in ereatinine clearance after a single TMP infusion was given to rats (Table 1 , upper panel). Acid-base status, plasma potassium (and other electrolytes) and aldosterone levels were similar to control. The slight, but significant, increase in urine sodium excretion seen in the experimental period of control animals was due to the volume expansion caused by the infusion of the salt solution use as the vehicle (Table 1 , lower panel). Following the same protocol, however, TMP-treated rats had a greater and significant natriuresis (P < 0.01) and bicarbonaturia (P < 0.01), as well as a decrease in urinary potassium excretion (P < 0.05). While TMP infusion did not change urine flow rate or chloride excretion, urine pH increased (P < 0.05).
Chronic administration. There was no significant difference in body wt between the two groups of animals after 14 days, indicating normal growth throughout the study. In control animals, mean body wt was 104 2 g on Day 0 and after 14 days, body wt was 177 4 g; in the TMP-treated animals, body wt was Abbreviations are: U.,,,, Urine flow rate (JAJ/min); UHcoV, urine bicarbonate excretion (nmol/min); UNaV, urine sodium excretion (nmol/min); UKV, urine potassium excretion (nmol/min); UV, urine chloride excretion (nmol/min), Exptl, experimental period; N = 6 in each group. a P < 0.05, b p < 0.01 vs. baseline of the same group and experimental of the control group Abbreviations are: U,,,, urine volume/24 hours (expressed/100 g body wt); U,03V, urine bicarbonate/24 hours; UNaV, urine sodium/24 hours; UKV, urine potassium/24 hours; U,V, urine chloride/24 hours; Pre, pre-treatment; Post, post-treatment; urine electrolyte excretion is expressed as sEq/100 g body weight/24 hours. N = 6 in each group. ap < 005 bp <0.01 Pre vs. Post TMP.
Despite the hyperkalemia, however, plasma aldosterone was not different from the controls (30 2 ng/dl vs. 28 2 ng/dl, respectively, NS). Chronic TMP therapy resulted in bicarbonatuna (P < 0.01) and a fall in urinary potassium excretion (P < 0.05) ( Table 2, In vivo effects of trimethoprim on renal A TPases Acute infusion. Na-K-ATPase activity in microdissected segments from TMP-treated rats was decreased by 36 0.9% in PCT (P < 0.005), 50 2.1% in CCT (P < 0.005), and 40 1.1% in
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MCT (P < 0.005) (Fig. 1) . TMP infusion had no effect on Na-K-ATPase activity in MTAL. Neither H-K-ATPase (Fig. 2 ) nor H-ATPase (Fig. 3 ) activity was affected in TMP infusiontreated animals (H-K-ATPase activity was examined only in collecting tubule segments).
Chronic administration. The effect of chronic treatment with TMP on Na-K-ATPase activity is shown in Figure 4 . Enzyme activity was decreased, as compared to control, by 45 2.6% in PCT (P < 0.005), by 73 2.0% in CCT (P < 0.001), and by 53 2,5% in MCT (P < 0.005). Chronic drug treatment, again, did not affect Na-K-ATPase in MTAL. H-K-ATPase activity in CCT or in MCT was not different from their respective controls (Fig. 5) . In contrast to the lack of effect of a single dose of TMP to alter H-ATPase activity in the collecting tubule (Fig. 5) , chronic TMP treatment decreased the enzyme significantly; in CCT, it was decreased by 21 1,3% (P < 0.05), and in MCT it fell by 24 1.5% (P < 0.05) (Fig. 6 ). H-ATPase activity, however, did not change in either PCT or MTAL. 
In vitro effects of trimethoprim on renal A TPase enzymes
To further examine the direct action of TMP on the three renal transport enzymes, we incubated the drug in vitro (0.01 to 10 mM) with tubule segments from normal animals ( Table 3 ). Tnmethoprim had a direct inhibitory effect on Na-K-ATPase in PCT, CCT, and MCT; it was without effect in MTAL, At 0.1 mri TMP, enzyme activity was decreased by 28 1.1% in PCT (P < 0.05), 30 1.1% in CCT (P < 0.05), and 27 1.3% in MCT (P < 0.05). There was a further, and significant, decrease in Na-K-ATPase activity in each of the three segments when the concentration of TMP was increased to 1,0 m. The percentage decrease, as compared to controls, was 53 4.2% in PCT (P < 0.01), 54 4,5% in CCT (P < 0.01), and 36 1.7% in MCT (P < 0.01). The highest concentration (10 mM TMP) did not decrease Na-KATPase activity further.
The highest concentration of tnimethoprim (10 mM) had no significant effect on H-K-ATPase or H-ATPase activity in any of the segments studied (Table 3) . In additional studies (N = 4), the effect of 0,1 mM (100 I.LM) amiloride was examined, This agent, well known to inhibit apical Na channels directly, did not change H-K-ATPase or 1-I-ATPase activity when it was incubated with collecting tubules microdissceted from normal animals, confirming results reported previously [19, 22] . However, this concentration of amiloride (100 ILM) decreased Na-K-ATPase in CCT from 905 26 pmol/mm/hr to 463 52 pmol/mm/hr (P < 0.01, N = 4). 
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Values are means SE expressed as pmol/mm/hr; N = 6 in each group. ND is not done (see Methods for details, 90 mm pre-incubation with TMP). a P < 0.05 vs. control "P < 0.01 vs. control and 0.1 mi TMP
Discussion
Trimethoprim is a widely used antimicrobial agent usually administered to humans as trimethoprim-sulfamethoxazole (Bactrim®) . While the physico-chemistry and pharmacokinetics in humans and other animals have been reviewed in detail in the past , abnormalities in renal function and electrolyte homeostasis seem to be occurring more frequently. Some of the renal disorders associated with trimethoprim treatment include decreased creatinine secretion, interstitial nephritis, and hyponatremia [2, 3] (Sulfamethoxazole appears to be without effect).
Recently, trimethoprim-induced hyperkalemia has been reported in patients with the acquired immunodeficiency syndrome (AIDS) who receive either high doses of the drug (20 mg/kg/day) or prolonged therapy (7 days or more) for Pneumocystis carinii pneumonia [4, 5] . The hyperkalemia appears to be reversible as it ameliorates after withdrawal of the agent [6] [7] [8] . The mechanism for the hyperkalemia is incompletely understood, but the reninaldosterone axis is reported to be intact in most, but not all, cases [5, 9, 27] . Metabolic acidosis has also been seen in patients without AIDS who received long-term high-dose trimethoprim, although its incidence is far less than is the hyperkalemia.
The collecting tubule plays a major role in potassium secretion and sodium reabsorption, processes which depend, in part, on the basolateral Na-K-ATPase pump. Inhibition of the enzyme would affect the transport of both actions. Sodium wasting would occur, although its magnitude may not be substantial if the enzyme were intact in other parts of the nephron. Net potassium balance in collecting tubule results as a combination of secretion via K channels and luminal reabsorption via activity in the H-K-ATPase pump localized to a intercalated cells. Inhibition of Na-K ATPase would result in hyperkalemia as the gradient across as the basolateral membrane would be dissipated. If collecting duct H-K ATP remained intact, K absorption would continue, making the hyperkalemia more profound.
Velázquez et al [11] recently reported that an acute infusion of trimethoprim inhibited potassium secretion and enhanced sodium excretion in the in vivo perfused rat distal tubule. The decrease in potassium excretion was 40% and the change in sodium transport was twofold. The drug had no effect on urine flow rate or chloride excretion, findings confirmed in the present study. Velázquez et al [11] also showed a 50% decrease in transepithelial voltage when 0.1 mM trimethoprim was perfused. This dose is comparable to the one which we showed to significantly inhibit collecting tubule Na-K-ATPase activity in vitro.
Recent electrophysiologic measurements in the A6 cell line demonstrate that 1 mtvi trimethoprim directly inhibits the amiloride-sensitive Na channel [28] . Apical, but not basolateral, administration affected the channels, suggesting that a direct interaction of the drug with the outer channel pore is required. Furthermore, the inhibitory effect of 1 mrvt trimethoprim on short-circuit current was rapidly reversed by the subsequent addition of amphotericin B (10-6 M) to the luminal bath [28] . The authors postulated that trimethoprim did not alter Na-K-ATPase or cellular metabolism since amphotericin B creates amilorideinsensitive ion channels allowing sodium to enter cells freely. They did not, however, measure Na-K-ATPase directly as we did in the present study. After either a single dose or chronic administration, trimethoprim was noted to inhibit Na-K-ATPase throughout the nephron, with the singular exception being the thick ascending limb. The pharmacologic agent also inhibited the enzyme when incubated in vitro. The discrepancy between electrophysiologic studies in an intact cell line in culture and our current biochemical studies in permeabilized cells are unknown. It appears that the A6 cell line is more sensitive (that is, current inhibition) to tnmethoprim. Our data, however, do support the notion that trimethoprim's inhibition of short-circuit current is secondary to its direct effect on Na-K-ATPase activity. We say this because in vitro incubation of normal tubules with 0.1 mM TMP is associated with a significant fall in enzyme activity; a greater decrease occurs if the concentration is further increased (that is, to 1 mrvt TMP).
An additional explanation, however, is that trimethoprim may affect both apical sodium channels (or potassium) and basolateral Na-K-ATPase equally. Amiloride, a drug chemically similar to trimethoprim, results in hyperkalemia when given chronically. Amiloride also inhibits Na-K-ATPase when added to proximal tubules on collecting duct segments in vitro [22, 29] .
The present study also shows that chronic tnimethoprim administration causes hyperkalemia but acid-base status and plasma aldosterone levels remain normal. Bicarbonaturia and a fall in urinary potassium excretion were noted. Na-K-ATPase activity decreased in a pattern similar to that observed in the short term study, however, a more prominent fall was seen in the CCT.
Again, H-K-ATPase activity remained unchanged, but collecting tubule H-ATPase activity was slightly decreased. Previous studies by our laboratory [18] , as well as by Garg and Narang [30] , clearly
show that hyperkalemia inhibits H-K-ATPase activity. In the present study, however, we found H-K-ATPase activity to be normal in TMP-treated animals, despite the hyperkalemia. This was an unexpected finding as the drug was not found to have a direct effect on the enzyme when incubated in vitro (Table 3 ). To us, this suggests that there must be offsetting events when the drug is administered ehronicalty, however, precisely what those events are remain unknown at the present time.
Hyperkalemia is a well known potent stimulus for aldosterone release [18] . In our studies, however, plasma aldosterone was normal after chronic trimethoprim administration, despite a plasma potassium of 5.6 mEq/litcr. Velázquez et al [11] reported in 7 of 30 patients with normal renal function receiving high dose trimethoprim (20 mg/kg/day) for a mean of five days, plasma potassium was 5.9 0.9 mEq/liter. Plasma aldosterone levels in these patients was slightly elevated with a mean of 19.3 9.5 ng/dl (laboratory control values were 8.1 to 15.5 ng/dl). In the face of hyperkalemia, we feel this is a suboptimal hormonal response, and combined with the result of our study, suggests that trimethoprim may indeed have a direct effect on the adrenal axis, possibly inhibiting aldosterone synthesis or release.
The kidney is known to avidly concentrate the drug [25] , but it is not known whether the same occurs in the adrenal gland. If a crucial step in aldosterone biosynthesis were inhibited, the hormonal response to hyperkalemia would be altered. If Na-KATPase is required for aldosterone release, trimethoprim may inhibit its activity in the zona glomerulosa in a manner similar to that we observed in the kidney. These possibilities would explain "normal" plasma aldosterone levels in the face of hyperkalemia.
Further studies are required to clarify this and to determine whether it is of clinical relevance in either normal or "at risk" humans.
Our experiments show, as has been reported in humans, that chronic trimethoprim results in bicarbonaturia, hut plasma bicarbonate and pH are normal. Such findings suggest that the drug stimulates tissue buffer stores, While liver, bone or muscle are the likely candidates for the enhanced extra-renal buffering, there are no data in the literature examining this issue. Since trimethoprim seems to be similar in many ways to amiloride, we searched the literature for its effect on extra-renal buffering; we were unable to find any data on amiloride, either.
Finally, our study shows that trim ethopim has no effect on Na-K ATPase in thick ascending limb, either in vivo or in vitro. While we have no ready explanation, it may be that there are different isoforms of the enzyme in this segment of the nephron as compared to other parts of the kidney. Further studies are required to verify whether this speculation is true.
In conclusion, acute trimethoprim infusion causes a decrease in urinary potassium excretion without hyperkalemia. This occurs in association with a fall in Na-K-ATPase activity in the proximal tubule and collecting duct. H-K-ATPase is normal. Long-term trimethoprim administration results in hyperkalemia as well as decreased potassium excretion. Na-K-ATPase activity was reduced in the proximal tubule, but a more prominent fall in the enzyme was seen in the cortical collecting tubule. After chronic administration there was a slight decrease in collecting tubule H-ATPase activity, possibly explaining the biearbonaturia. In vitro, trimethoprim causes a direct inhibition of Na-K-ATPase activity in a dose-dependent fashion; the drug does not alter the HATPase or H-K-ATPase activity in vitro. Trimethoprim must also exert a direct effect on the adrenal axis as plasma aldosterone was within the normal range despite the rather marked hyperkalemia. Taken together, these data suggest that, from a functional standpoint, trimethoprim "is" amiloride, and should be used judiciously not only in the immunocompromised patient, but also in patients with renal insufficiency.
